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Abstract: 
This report could be summarized has having a scientific and an ethical discussion part. The 
scientific part includes general information about different types of stem cells; furthermore, it 
provides information on the medical uses, and the medical risks that are associated with stem 
cells. In addition, basics on ethics and bioethics was added at the end to ease the progression 
of the scientific part in to the ethical discussion, that way the reader didn’t become 
overwhelmed with the introduction of new material. Eventually, this leads to the discussion 
of the ethical dilemma with the origins of embryonic stem cells by presenting arguments and 
counter-arguments, allowing an unbiased analytical view on the debate of stem cells. The 
ethical viewpoint of American society was able to influence future research of stem cells by 
creating and enforcing legislation. The end result being the creation of iPSCs, that show 
promise as an alternative to embryonic stem cells. 
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1. Introduction 
  Stem cells are cells that can change into undifferentiated cells through symmetric or 
asymmetric division. It is this and the ability of long term self-renewal that defines stem 
cells. In addition, stem cells resemble cancer cells because they can resist apoptosis, and for 
other reasons, which ultimately create risks in their usage. For this reason only adult stem 
cells have been used to treat medical conditions and only in very limited amounts.   
Embryonic stem cells, which are pluripotent, can differentiate into all three different germ 
layers. On the other hand, Adult stem cells can only change into a certain type depending on 
where they are extracted from in the body. The limits of the adult stem cells to differentiate is 
the reason why scientists favor embryonic stem cells over their counterparts; however, the 
ethical issues surrounding the origins of embryonic stem cells was its fatal flaw.  
 
 Originally stem cell research was focused on embryonic and adult stem cells alone; 
however, each kind carried its own fatal drawback. Scientists have noticed the potential of 
stem cells in regenerative medicine, but the drawbacks have definitely hindered the usage 
potential. In respect to this, researchers found an alternative that worked around the 
drawbacks and combined the strengths of the two types of stem cells. The basis of this paper 
is to look at the progress of stem cell research and more specifically, looking at how ethics, 
biological issues, and medical risks influenced this progress.   
1.2 Problem Formulation 
 How has ethics had an impact on the research of stem cells over time and has the 
medical risks and biological problems affected this research? 
We expect to see a struggle between using embryonic stem cells and adult stem cells due to 
societies ethical beliefs and the efficiency of the two categories. In addition, we believe we 
will see research shying away from embryonic stem cells due to ethical considerations and 
pressures from governments, and rather focus on alternatives (i.e. induced-pluripotent stem 
cells), which could give us the same abilities as embryonic stem cells without the cost of a 
human embryo.  
1.3 Theme 
 The theme in the third semester is “Reflection on natural science and the 
dissemination of knowledge in the field of natural science.” This project looks at how society 
has influenced the development of stem cell research, and the history can show the path the 
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research has taken due to the influence of society. Therefore, this project looks at science 
from the sociological perspective to reflect on natural science. 
1.4 Target Group 
 This project isn’t just about a certain subject in science, but rather science as a whole. 
Whether biology or chemistry it is important to know that society through cultural or political 
beliefs can influence the course of research and development. In that case, this project could 
be directed to any natural science student. Specifically, this project could relate to any person 
pursuing or in the medical field. 
2.  Background 
 Stem cells are generally defined by two main properties: the capacity for long-term 
self-renewal, and the ability to differentiate into one or more sister cells. Stem cells are 
therefore defined as somatic cells that have the ability of perpetuating themselves through 
self-renewal or mitosis into two undifferentiated cells or to generate new cells of a particular 
tissue through differentiation. They’re two different types of division stem cells go through, 
and those are symmetric and asymmetric division. The symmetric division is related to the 
ability of the cells producing two undifferentiated cells, while asymmetric division produces 
one undifferentiated stem cell and a sister cell which will differentiate some point in time.  
Stem cells are rare in most cells and therefore they must be identified prospectively and must 
also be carefully purified in order to study its properties (Spragunde, et,al. 1988). Stem cells 
are capable of renewing, repairing, and replacing damaged cells in the body. Thus they are 
extracted and deposited into the body, for tissue maintenance, growth, and repair (Vessey, De 
La Hall, 2001). 
 
 There have been several studies on the use of stem cells, and few instances have been 
identified regarding its usage. One instance is the identification and the isolation of 
haemotopoietic cells from mice and humans that have shown to be responsible for the 
generation and regeneration of the blood forming immune system. Stem cells from different 
tissues are likely to have the potential to be used in therapy in the near future. 
Haemotopoietic cells, which is the vital element in the bone marrow transplant have been 
used to set up therapeutic strategies for the treatment of solid tumours, such as 
gynaecological solid tumour (Perillo et,al, 0000/Akashi, Weissman, 2001).In mammals, the 
two broad types of stem cells are the embryonic stem cells and adult stem cells. The main 
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important stem cells include embryonic stem cells, fetal stem cells, adult stem cells and 
nuclear transplant stem cells 
2.1  Embryonic Stem Cells 
 These stem cells are isolated from undifferentiated inner cell mass or blastocysts. 
They are collection of cells that are derived from early embryo and they are able to give rise 
to many different kinds of organs and tissues (Pera et, at. 2001). ESC cells have prolonged 
self-renewal capacity and are pluripotent. Before the mammalian embryo is about a week 
old, its cells can grow into various types of cells. These cells can develop and turn into tissue 
types in the actual fetus. Figure 1 gives an illustration on how the ESCs are identified. 
 When embryonic stem cells undergo differentiation, as a result of the protein encoded 
by the genes of the embryo, there is a tissue rejection that can occur and this has been an 
obstacle to researchers. The body turn to reject it since it registers it as foreign when they are 
introduced into the body system of humans. Fortunately there has been advancement in 
creating stem cells through the manipulation of cell and egg which sounds promising without 
necessary creating a special embryo (Kiessling, Anderson, 2003)
 
2.2  Adult Stem Cells 
 These are undifferentiated cells which can be found throughout the mammalian body 
both in children and adults that can renew itself and can differentiate to give rise to some or 
all the major specialised cell types of the tissue or organ. Its basic role is the ability to divide 
to replenish dead cells and regenerate damage tissues in which they are found. Unlike ESC, 
the use of adult stem cells has not brought many controversies since it does not involve the 
destruction of an embryo. ASC definition actually requires the two properties it possesses: 
self-renewal thus the ability to go through several cycles of cell division whiles maintaining 
its undifferentiated condition.  
 Also the ability to generate new cells from several distinct cell types is another 
property that defines adult stem cells. They have been found in organs and tissues such as 
brain, bone marrow, skeletal muscles blood vessels, teeth, testes etc. In general Adult stem 
cells can be subdivided into groups, depending on the cell surface markers, morphology, their 
differentiation potency and the cell from which they originate. Some few examples of ASC 
include mesenchymal/ Stromal cells, endothelial progenitor cells and haematopoietic stem 
cells. 
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Adult Stem Cells (ASC) Embryonic Stem Cells (ESC) 
Differentiate into limited number of cell 
types 
Show greater differentiation potential 
Are not easily grown after isolation from 
the tissue 
Show almost unlimited division, or 
proliferation 
The patient's own cells are identified Can be grown fairly easily 
The immune system is less likely to reject 
the cells 
There is need for strong immune suppressing 
drugs 
Table 1: shows the main differences between ESC and ASC. 
2.2.1  Haematopoietic Stem Cells 
 Haematopoietic stem cells are blood cells that give rise to other blood cells: red blood 
cells, T lymphocytes, B lymphocytes, natural killer cells, neutrophils etc. Haematopoietic 
cells from mice and humans that have shown to be responsible for the generation and 
regeneration of the blood forming immune system. Stem cells from different tissues are 
likely to have the potential to be used in therapy in the near future. Haematopoietic cells, 
which is the vital element in the bone marrow transplant have been used to set up therapeutic 
strategies for the treatment of solid tumours, such as gynaecological solid tumour (Perillo 
et,al, 0000/Akashi, Weissman, 2001). Umbilical cord blood stem cells also fall under 
haemotopoietic stem cells. These stem cells are the blood that is left in the placenta and the 
umbilical cord after child delivery. That is after the delivery of a baby and the umbilical cord 
are cut, there are some blood that remains in the blood vessels of the placenta and the 
umbilical cord, which the baby no longer needs it after birth. Because Cord blood is a type of 
haematopoietic stem cell they can be used in transplantation as a replacement to bone 
marrow, and also in the treatment of most diseases. (Koo, Ahn, 2012). 
2.2.2  Mesenchymal Stem Cells 
 Mesenchymal/ Stromal cells are multipotent adult stem cells. They are composed of 
different specialised cells found in the skeletal tissue. They can for example differentiate into 
cartilage cells (chondrocytes), bone cells (osteoblast), fat cells (adipocytes) and other 
connective tissues found in tendons as illustrated in the figure below (NIH, 2012).  
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2.2.3  Endothelial Progenitor Cells 
 Endothelial progenitor cells are described as a rare population of non- haematopoietic 
that are found in the bone marrow, which supports the integrity of vascular endothelium. 
(NIH, 2012) 
  
 
Figure 1: Hematopoietic and Mesenchymal/ Stromal cells differentiatio    (© 2001 Terese Winslow) 
2.3  Induced Pluripotent Stem Cells 
 The main advantage of Induced Pluripotent Stem cell (iPSC) is that they are derived 
from terminally differentiated cells, such as skin fibroblasts or B lymphocytes, without the 
need for human embryos or oocytes. This means that they do not have the ethical and 
political baggage of human ESC’s. Furthermore, the method for generating iPSCs is 
relatively simple and achievable by most laboratories using standard techniques and 
equipment. (Hanley, et. al. 2010) 
 
 Adult stem cells can be genetically reprogrammed to change into an embryonic stem 
cell-like state. This is done by forcing it to express factors and genes, which are important for 
maintaining the properties defining embryonic stem cells. These are called Induced 
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pluripotent stem cells (iPSCs). Even though these genetically reprogrammed adult stem cells 
follow the guidelines for pluripotent stem cells, it is unknown whether or not embryonic stem 
cells and iPSCs vary in clinically significant manners. Mouse iPSCs (MiPSCs) were first 
reported in 2006 about a year before human iPSCs in 2007. MiPSCs show imperative traits 
of pluripotent stem cells such as expressing stem cell markers as well as forming tumors that 
contains cells from all three germ layers. MiPSCs have shown the ability of contributing to 
various different tissues, when injected into mouse embryos. Just like mouse iPSCs, human 
iPSCs can express stem cell markers and they can generate cell characteristic of all three 
germ layers (Bethesda, 2013). 
3.  History 
 Stem cells were first discovered in the mid 18th century when they were found in the 
analysis of embryo development and bone marrow in Germany. (Stem Cell Network, 2009) 
 Stem cell research soon became an acknowledged study, and with it, came ethical and 
political issues. These issues had and still have a huge influence on the outcome and 
development of the study. Biologists have been expected to engage in ethical debates on the 
background of political and ethical issues towards the research of stem cells. Throughout the 
history of stem cell study, a positive outcome on benefits from the use of stem cells has 
seemed promising. Researchers have been working on cures for diseases such as Alzheimer’s 
and leukemia. (Robin Lovell-Badge, 2001) 
 As the research developed, observations confirmed that stem cells could possibly 
yield other cells, developing stem cells into progenitor cells to other human cells. (Jonathan 
H, Denae M, Christopher N, Neil P, 2010) 
 As stem cell research has grown bigger and developed so has the ethical viewpoint 
about these developments. The study has shown good potential for a better understanding of 
medical conditions but the method of the research has over time caused a great deal of 
interest and public debate. Especially one kind of stem cell - the human embryonic stem cell 
- has caused concerns regarding ethical beliefs. (Stem Cell Information, 2013) 
 The regulation of stem cell research has been a big topic for many years all. In major 
parts of the world, there are no laws against embryo research but in some parts of Europe it is 
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strictly regulated. Since the beginning, stem cell research programs have been shot down due 
to ethical or political issues. (R.M.L. Winston, 2007) 
 In 2001, President George W. Bush limited the government funding for the study of 
stem cells obtained from human embryos, as he believed the technology used resulted in 
destruction of human life. According to Bush, stem cell research devalues human life due to 
the fact that embryos have to be destroyed in order to extract stem cells. Bush's ban resulted 
in a slowed down progress of stem cell research by removing the government funding and as 
a consequence American scientists set up labs abroad to continue their research. (Alice Park, 
2012)  
Bush’s policy did not stop stem cell research, basically because he could only ban federal 
funding, but the private and public-private (state level) funding could not be regulated, also 
the funding only stopped the creation of embryos for research or to derive new cell lines from 
embryos, while permitting use of stem cell line already in existence. California is the best 
example on how the ban was bypassed by some of the states, where in 2004, a referendum 
was passed to allow an investment of 300 million a year to a stem cell research 
institute.(Cahill, 2005) 
 In January 2003, the International Stem Cell Forum (ISCF) was founded with the aim 
to promote biomedical science and funding support for stem cell research. 14 leading 
founders of stem cell research from around the world are part of the foundation. 
(International Stem Cell Research, 2012) 
 In 2004, the International Consortium of Stem Cell Networks (ICSCN) was initiated. 
Their aim is “to make stem cell therapy a reality for a broad range of debilitating diseases by 
unifying international efforts” (Stem Cell Network, 2009). 
 In 2009, President Barack Obama made it possible for scientists relying on federal 
funding to use excess embryos from In Vitro Fertilization (IVF) procedures to obtain stem 
cells for study by lifting George W. Bush' restriction. (Alice Park, 2012). Nevertheless 
ethical and political issues still play a huge role in the field of stem cell research.  
Great knowledge has been gained due to research with stem cells; new understanding about 
the way of how some life threatening diseases work and how to treat them has arose from 
various successful trials, but some of these advantages have not yet been implemented, in 
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some countries, due to different laws concerning certain ways of using stem cells and what 
they can be used for.  
Below are few examples of what is permitted in which European countries:   
 In Austria, embryonic stem cell research is banned. In the Czech Republic, embryos 
research is permitted but reproductive cloning is banned. Stem cell research has no specific 
legislation in Ireland and in Spain and the United Kingdom, stem cell research has a 
comprehensive regulatory framework but Spain also has laws and regulations applied to 
different aspects of the research and how it is used. (EuroStemCell et al. 2008-2013) 
4.  Medical Risk 
 Stem cell therapy is still in a very experimental stage, where only a few proposals for 
stem cells have actually been used. As such, the medical risk factors and biological problems 
have still not been completely investigated. There are many risk factors, some have been 
confirmed, and others have only been reported. In addition, some risk factors are only viable 
for certain types of stem cells. Types of risk factors could be the type of stem cells used, how 
they are gathered and their history, the level of manipulation, and their site of injection 
(Herberts et al. 2011). Because there are so many risk factors, we’ll divide them into three 
categories: intrinsic, extrinsic, and clinical. 
4.1  Intrinsic Factors 
 Intrinsic factors are based on the actual cellular properties of stem cells. The different 
intrinsic properties in stem cells all influence the risk factor of tumour formation. Stem cells 
have properties similar to cancer cells such as, long life span, apoptosis resistance, and the 
ability to replicate for an extended period of time. Because of these properties they also have 
the ability to form malignant tumours (Herberts et al. 2011). Embryonic stem cells (ESC) can 
only be allogeneic, coming from a different individual, and have a higher chance of tumour 
formation. For example, a case study of a male who received neural stem cells was later 
diagnosed with a multifocal brain tumour, and after analyzing the transplanted neural stem 
cells they discovered that the stems cells originally came from two embryos (Amariglio et al. 
2009). On the other hand, adult stem cells (ASCs) can be allogeneic or autologous material, 
cells come from the same individual, meaning that there are less likely to be rejected by their 
immune system and form tumours (Herberts et al. 2011).  
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 Other factors that come into play for tumour formation are the potency 
(multi/pluripotent) and the site of administration. With potency we look at the ability of the 
stem cells to differentiate into other cells. Tumour formation is more likely to form with stem 
cells that are pluripotent then multipotent; therefore, it is preferred that stem cells are 
converted into the needed specialized cell before they’re administered to a patient to reduce 
the risk of tumours (Herberts et al. 2011). Furthermore, when regarding the site of 
administration, a stem cell’s environment may influence its tumour potential. More 
aggressive formation of tumours was shown when ESCs were transplanted to the same 
species; however, a xenotransplantation, taking living cells from one species to another, 
between rats and mice showed that a tumour didn’t form (Erdo et al. 2003). 
4.2  Extrinsic Factors 
Extrinsic factors include procurement, manufacturing, and handling of stem cells. 
This includes the culturing of stem cells in vitro, genetic modification, and adventitious 
agents. Evidence suggests that the culturing of stem cells in vitro is the cause of increased 
tumour formation. In vitro culturing has shown to sometimes mutate the stem cell’s 
characteristics that interfere with important functions like the cell cycle and DNA repair 
(Herberts et al. 2011). Before use, stem cells may need to go through an extensive reform 
through genetic modification especially induced pluripotent stem cells (iPSC), adult stems 
modified into pluripotent stem cells. To generate iPSCs, retroviruses and lentiviruses have 
been used. The viruses are genetically modified to encode genes into the stem cells, which 
are required for the transformation. The integration of the viruses can cause adverse effects 
by reactivating cancer-causing genes also called oncogenes.  
Severe epigenetic changes of chromatin have also been observed with the generation 
of iPSCs; however, there is limited research on what these side effects could cause (Herberts 
et al. 2011). This may make it seem that the transformation of stem cells is very hazardous, 
but techniques have been created to detect and get rid of oncogenes. In addition, viruses are 
not the one technique to generate the iPSCs. Proteins, chemicals, and plasmids have also 
been used and shown to have less tumour formation potential. Below on table 2 is a list of 
different methods of delivery and their advantages and disadvantages. Adventitious agents 
are microorganisms that contaminate medicinal products, which in this case are stem cells. 
Avoiding contamination is elementary lesson everyone learns in the lab, but it is a very 
important fundamental because even the slightest contamination can result in death or other 
serious side effects. Proper donor histories for allogeneic transplantations are necessary to 
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avoid transmission of diseases. Of course materials that are intentionally used to supplement 
stem cells cultures can also cause undesirable effects, such as the use of fetal bovine serum 
(FBS) that can transmit diseases and cause immunological rejection (Herbets et al. 2011). To 
reduce the risk of transmission, testing for adventitious agents is a simple matter. 
Contamination can be more serious because of the use of immune-suppressive drugs for 
some stem cell therapies. 
Table 2: Methods of Delivery  
Method Advantages Disadvantages 
Moloney based 
retrovirus     
-Silencing in pluripotent 
cells 
-self-silencing/ no need for 
timed factor withdrawal 
-risk of insertional mutagenesis 
-limited to dividing cells 
- expression often maintained/ increased 
tumor generation  
HIV-based 
lentivirus     
Constitutive    
Transduction of both 
dividing and nondividing 
cells 
Inducible 
temporal control over 
factor expression 
________________ 
risk of insertional mutagenesis 
lack of silencing in pluripotent state 
________________ 
risk of insertional mutagenesis 
possibility of leaky expression 
Transient 
transfection 
-no viral components 
-low genomic integration 
-technically simple 
procedure 
-multiple rounds of transfection are required 
-lower levels of expression than when 
integrated 
-delayed kinetics of reprogramming 
-integration provides selective advantage and 
necessitates clone screening  
Adenovirus low genomic integration -repeated infection for certain cells types 
-delayed kinetics of programming 
-risk of generating tetraploid cells 
Table 2: List of advantages and disadvantages of different methods of delivery of iPSCs (Maherali, Hochedlinger, 
2008). 
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4.3  Clinical Factor 
The immune system plays a pivotal role in defending our bodies from foreign 
substances, but in the case of transplanted stem cells can end up hurting the individual. When 
transplanting stem cells into a patient the immune system can detect the foreign substance 
and elicit an inflammatory response that can destroy the donor cells by forcing apoptosis. In 
addition, it can also cause graft versus host disease (GVHD), which causes the donor cells to 
attack the regular cells in the body. Of course it is much more likely that allogeneic 
transplantation will cause rejection then an autologous transplantation, which has to do with 
compatibility. In order to see if the donated cells are compatible, scientists use human 
leukocyte antigen matching (HLA) (Herberts et al. 2011).  
 
HLA is a set of genes that code for the major histocompatibility complex (MHC), 
which are molecules on the membrane of cells that interact with leukocytes, or white blood 
cells. The more similar these MHCs have with the patient receiving transplanted material the 
better. For example, in an experiment researchers compared two mice hearts, one being 
allogeneic and the other syngeneic, came from identical twin. The data showed that within 
three weeks, the inflammatory response with allogeneic heart was much greater than the 
syngeneic heart, and after 5 weeks it was so severe that 90% of the grafted cells were 
destroyed. On the other hand, the syngeneic heart had very little inflammation proving the 
necessity of HLA-matching  (Nussbaum et al. 2007). However, MSCs have shown to have 
low immunogenic potential meaning it is less likely to provoke an immune response 
regardless of the compatibility.  
 
In order to decrease the chance of rejection doctors prescribe immunosuppressants to 
decrease the efficiency of the immune system and allow the transplanted cells to survive. 
These immunosuppressants work in different ways and are necessary only in certain 
moments of the transplantation process. Some modes of action are inhibition of T-cells, 
disruption of the synthesis of DNA, RNA, and/or cell division, and suppressing 
inflammation. The side effect of immunosuppressants is dependent on the drug; however, 
their purpose is also dangerous because it lowers the efficiency of the immune system 
leaving the patient susceptible to infection. (Prescilla et al. 2013). Other strategies have been 
formulated instead of using immunosuppressants, which include the banking of stem cells 
with MHC backgrounds, and genetically modifying them to fight immune rejection (Herberts 
et al. 2011). Refer to figure 2 for a list of medical risks in each category.  
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Figure 2: A table that shows the risk factors associated with stem cell therapy (Herberts et al., 2011). 
5.  Diseases   
5.1  Lukemia 
 Leukemia is a cancer of white blood cells, or leukocytes, which are in charge to fight 
off infections in our bodies. According to the University of Utah, the success of the treatment 
for leukemia depends on: “getting rid of all the abnormal leukocytes in the patient, allowing 
healthy ones to grow in their place”. The most common medical approach is to do this is 
through chemotherapy, which uses potent drugs to target and kill the abnormal cells. In 
certain cases, when chemotherapy alone is not effective enough, bone marrow transplants are 
a possible option to treat the disease. 
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 In a bone marrow transplant, bone marrow stem cells are replaced with those from a 
healthy, matching donor, the stem cells help stimulate new bone marrow growth and restore 
the immune system. 
The idea behind this method is that, the stem cells will migrate into the receiver bone marrow 
and begin producing new, healthy leukocytes to replace the abnormal cells. 
 Before the transplant high doses of chemotherapy are given to destroy as many 
leukemia cells as possible. In some cases, radiation therapy is also implemented in order to 
weaken the disease and ensure that the risk of rejection is minimized. 
5.2  Alzheimer’s Disease 
 Alzheimer's disease (AD). Is a progressive brain disorder that damages and 
eventually destroys brain cells, leading to memory loss and changes in thinking and other 
brain functions (Alzheimer’s Association, n.d.) It usually develops slowly and gradually gets 
worse as more brain cells wither and die. Ultimately, Alzheimer's is fatal, and currently, there 
is no cure. 
 Current AD therapy serves only to reduce the degree of impairment and improve the 
quality of lives of patients, but the disease cannot be prevented or cured. 
 Due to the potential of stem cells to remain undifferentiated, they may provide an 
unlimited cell source for replacement in a number of aging-related neurodegenerative 
diseases such as AD. Experiments have shown that human neural stem cells (NSCs) 
transplanted into aged rat brains can differentiate into neural cells and significantly improve 
the cognitive functions of animals, further pointing to NSCs as a promising candidate for 
neuro-replacement therapies (Zhongling et.al, 2009). 
 Even though the treatment of AD seems promising there are still some questions that 
must be answer for stem cell therapy to be used in the aging brain. Especially the issue 
capability of the aging brain to respond and produce signals after the disease-related changes 
affects it. 
 Also the important amount of cell death of the transplanted cells posts a challenge 
that has to be taken into consideration. 
 And as Zhongling et.al. defined it many key issues are still required to be elucidated 
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and cautioned, such as the source of stem cells for treatment, isolation, and characterization, 
cell dosing (how many cells are enough for therapeutic efficacy), dosing schedule, 
administration route, short-term or long-term side effects caused by cellular therapy, and so 
on. 
5.3  Cardiac Regeneration 
 Cardiac regeneration. Debilitation of the myocardium, caused by different reasons, 
may lead to a possible heart failure. At the moment the only standard therapy for heart failure 
that addresses the problem of cardiomyocyte loss is cardiac transplantation. 
 New discoveries on the regenerative potential of stem cells for treating and 
preventing heart failure have transformed experimental research and led to an explosion in 
clinical investigation (Segers and Lee, 2008). 
 Myocardium, unlike any other muscle of the human body, shows a relative low 
regenerative capacity when affected by myocardial infarction or other myocardial diseases, 
and here is where stem cell therapy (SCT) may be very useful, due to the potential of the 
cells to specify and regenerate the lost myocardium. 
 There are challenges that have to be overcome in order to be able to move towards a 
successful SCT, such as knowing which type of stem cell is the best candidate for therapy. 
Seegers and Lee wrote: Bone-marrow-derived progenitor cell therapy has thus far proven 
safe and beneficial, but the cells’ regeneration potential is controversial. ESCs have the 
greatest differentiation potential, but face ethical barriers and also have the greatest risk for 
teratoma formation. 
 As seen with the 3 examples SCT is a viable and, so far, rather efficient alternative to 
face some important diseases that have so had none or very complicated treatment. 
6.  Basic ethical guidelines 
 There are several basic ethical guidelines in play when talking about stem cell 
research. According to some, the use of human embryos in research represent manipulations 
of human life as well as undermine human dignity. Others states that it is a moral obligation 
to heal diseases and that it is a promotion of human dignity. As a direct result,  the 
undifferentiated blastocyst cells that yield human embryonic stem cells are a resource that 
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should not be dismissed despite the moral issues this may carry.  It is therefore necessary to 
have guidelines regarding stem cell research due to the ethical perspectives. To respect the 
donor and respect the confidentiality is one of many guidelines that applies in the process of 
obtaining a human embryo.  
 The committee for Human Embryonic Stem Cell Research has examined various 
guidelines that has been used in the past as well as now and even though it differs from 
country to country, there are a couple that are worldwide. "A prohibition on the culture of 
human embryos beyond 14 days after fertilization or when the primitive streak has appeared, 
whichever occurs first" is a guideline that is agreed on by every country working with human 
embryonic stem cell research. Another is the fact that human embryonic stem cell research 
projects are required the aim to benefit human health by advancing medical and scientific 
knowledge. In addition, Alternative methods, such as adult stem cells has to have been 
examined and shown to be insufficient for projects before the use of new human embryonic 
stem cells are approved. The most important guideline is the one stating that one's' research 
must follow the scientific and ethical standards and must only be conducted in accordance 
with all the regulatory requirements of the state. (National Research Council and Institute of 
Medicine of the National Academies, 2005). 
 By 2005 the U.S. National Academy of Science issued ethics guidelines for stem cell 
research, allowing the creation of embryos for research, including the ones created from 
combined human and animal gametes, given that no primate gametes are used and that the 
embryos have not grown for longer than 14 days (National Research Council and Institute of 
Medicine of the National Academies, 2005). 
7. Bioethics 
 Bioethics, like general ethics is a philosophical discipline concerning morals, what is 
right and wrong in different cases. Where ethics in general pertain various fields, bioethics 
only apply to the field of medicine and healthcare. Bioethics contain history, philosophy, 
theology and law with health policy, medicine and medical humanities which gives an insight 
of several disciplines on the interaction of science, human life and technology. One of many 
aims in bioethics is to figure out how medical technology can alter the way humans 
understand the meaning of health as well as illness. (Center for practical bioethics, n.d) 
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 Research has inevitable been delimited by our own morals, and views on ethical 
issues. The concepts of right and wrong dictates most human actions, and these paradigms 
are translated into a macro scale, in science and politics.  
 
 Specifically for science these concepts are important, due to the controversy that 
revolves around scientific knowledge. As an answer to this conflict specific guidelines are 
created for very specific purposes. The main role of bioethics is to ensure that science works 
in accordance to the ethical paradigms of society by dictating parameters about how, when 
and what kind of research can be done. For the specific case of stem cells, much has been 
said regarding their problematic origin, especially for embryonic stem cells.  
 
 In 1994 the Human Embryo Research Panel (HERP) from the National Institutes of 
Health (NIH) was in charge of classifying human embryo research into three categories: 
acceptable, needing additional review, and unacceptable. HERP also drafted guidelines for 
the review and conduct of acceptable research. The Advisory Committee of NIH 
unanimously approved the report, but President Clinton issued a statement saying, "I do not 
believe that federal funds should be used to support the creation of human embryos for 
research purposes, and I have directed that NIH not allocate any resources for such research." 
(The President's Council on Bioethics n.d). 
 
 When discussing the controversy of using human embryos for research purposes the 
basic issue that surfaces can be traced to 1994, when the HERP declared, after much 
discussion, that embryos could not be granted personal status because they don’t show the 
properties of a human being, at the same time they couldn’t accept the view of embryos as 
mere property (Holland, et.al. 2001).  
 
 The aim of the HERP was to create a kind of middle ground, without picking a side 
between deontology or utilitarianism, the result of this lack of compromising did not help to 
solve the issue, on the contrary it made more evident that there is no consensus on what the 
embryo is and what is its moral status. 
 
 But the ethical issue cannot be solve by a human body, since society is open to 
debate, it is virtually impossible to reach a final conclusion were the question of right of 
wrong is answered in accordance to all ethical views. Consequentially the role of any 
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bioethics body resides in give guidelines by taking in consideration all the possible ethical 
issues that may arouse from science. 
8. Discussion   
 The debate on the ethics of stem cells is controversial due to the way of obtaining 
some of the cell lines, the most clear example are ESCs, which are obtained from the death of 
at least one embryo. However, when talking about the use of embryos it necessary to know 
that initial human ESC lines were derived from ‘spare’ embryos produced by in vitro 
fertilization, and donated with the informed consent of the parents (Rippon, Bishop, 2004). 
The easy way around this dilemma would be to use ASC, which didn’t destroy a human 
embryo. Although, ASCs had a drawback as well because it didn’t have the same ability to 
differentiate as ESC, nor was it as effective. Meaning the goal of stem cell therapy is to find 
an alternative that does not sacrifice efficiency for the sake of being ethically correct. 
8.1  Embryonic Stem Cells 
 The research of embryonic stem cells creates a moral problem because it debates two 
highly valued fundamental moral principles. The first is the obligation to respect the value of 
human life and the second is to prevent suffering. When it comes to embryonic stem cell 
research both principles simply can't be respected simultaneously. When extracting human 
ESCs it defies the obligation to respect the value of human life as it results in destruction of 
the embryo, which could possibly have become a human life.  Should the first principle have 
priority rather than the second in this conflict? Because ethics is an opinion related subject, it 
can't be decided whether the first principle weighs more because it respects the value of a 
possible human life, and destructive embryonic stem cell research should therefore be 
prohibited. However, some people consider it to be ethically superior to use these embryos 
for medical research from which the human population as a whole is likely to benefit, than to 
simply destroy them or store them indefinitely. (Rippon, Bishop, 2004). Of course people 
began arguing the status of embryos, whether embryos achieved personhood at fertilization, 
birth, or sometime in between during development. 
 
Some people believe that once an egg has been fertilized it has achieved a moral 
status equal to that of an adult or child. In this ideology a human embryo is exactly that, a 
human. It does not matter what stage of development it is in because of the belief that all 
humans are worthy of respect. One wouldn’t demean or disrespect the life of a child to that of 
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an adult merely based on the fact that the adult was more developed; hence, the stages of 
development should have no part it deciding when a human is a human. On the other hand, 
some would argue that the comparison between embryo and child, and child and adult is 
different based on the development of intellectual, physical, and emotional capabilities. 
(Hug, 2006). 
 
Those that believe that the moral status of an embryo is dependent on the stages of 
development have specific individual thoughts at what stages the embryo becomes a person. 
For example, around the 21st day after fertilization ultrasound can detect a heartbeat, and 
some people this development is the period an embryo has achieved personhood. Others 
argue that it isn’t till the nervous system has formed in week 4 that it can be considered a 
human life; although, brainwaves aren’t recorded until day 40. The reason why the nervous 
system is used as a standard is because one can compare the moral status of an embryo to that 
of a brain dead patient. The train of thought being, “Organs are extracted from brain dead 
patients, so why couldn’t stem cells be extracted from embryos (Hug, 2011). 
 
The period an embryo becomes a person is specific from person to person, based on 
individualistic ideologies. Sometimes it isn’t until a certain organ has formed, which gives 
the embryo the capacity to think or sense something. Sometimes it isn’t until it moves or 
looks like a human. However, It is because of these reasons why some people believe that 
deciding when an embryo is human is wrong. One could think that the protection of life 
shouldn’t be on what the universe thinks of a being, but what that being thinks about it’s own 
self worth. Continuing on this argument, one shouldn’t make rash assumptions to end a life 
based on an uncertain period of when an embryo is a person worthy of life (Hug, 2006). 
 
 On a completely different side of the spectrum are those that believe that embryo/ 
fetuses have no moral status until born. They believe that the embryo is entirely dependent on 
the mother, and as such, has no say or control. The embryo is merely organic material that 
resides inside the mother; therefore, the embryo is the property of the mother. Furthermore, 
to harm the embryo it must have interests and to have interests it must have goals or a 
purpose, which it does not (Hug, 2006). 
 
 The discussion around the real status of an embryo diverges greatly in society, and 
even though many people support full human status , it is adopted mostly in a philosophical 
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sense, hence is hasn’t been adopted as a matter of cultural practice. A clear example of the 
ambiguity of the discussion, is the way the natural loss of an embryo in normal human 
reproduction is not recognized as a death that requires a funeral, and the disposal of human 
embryos after completion of infertility treatments is not treated as murder by the legal system 
(National Research Council and Institute of Medicine of the National Academies, 2005). 
8.2  Political Decision 
In 2001 George W. Bush talked about the topic of stem cell research:  “My position 
on these issues is shaped by deeply held beliefs,” he also cited concerns that such research 
devalued human life. (Park, Alice. 2001). This statement marked the end of any federal 
funding for research on stem cells. But the true meaning of this statement goes beyond the 
mere religious view. Without even knowing it Bush used one of the bases of the Kantian 
ethics, by stating that life is superior than any end, regardless of the beneficial outcomes, 
very opposite of what the consequentialist theory dictates: ¨In principle, if not in practice, a 
consequentialist may be required to sacrifice an innocent person for the sake of some greater 
good¨ (Cummiskey, David. 1990). 
 
            Bush's ban created an exodus of scientists that start working in different countries 
where laws were either more flexible or non-existent, most of them trying to overcome the 
ethical challenges that limited [stem cell] research. It was for this reason that research into 
alternatives for ESCs developed and progressed into the discovery of iPSCs. 
 
One of the most important issues has always been the use of human embryos in the creation 
of ESC’s, the most extreme positions, like George W. Bush, condemn the total use embryos 
as a means to an end regardless of the outcome; for the specific case of this work the 
treatment of incurable diseases. This position is rather appealing to a large portion of people 
due to the implication of greatness, nothing is above human life, it gives a god like status to 
the human species. A by product of this view is the notion that science has no moral limits 
when it come to find a solution to a given problem, thus creating the sense that scientific 
research is based upon consequentialist ideas.  
 
            From an ethical point of view, the discussion centers around the fact that “unwanted” 
embryos can be potentially useful in research, but how morally correct would this be? If the 
assessment were based purely on a consequentialist view, it would be a moral duty to use 
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them to fulfill a higher moral goal. In contrast to this, one could argue that the concept of 
what is right relies deeply in personal experiences and beliefs (Alexander & Moore .2007), 
therefore giving the discussion a more confidential and individual dimension. 
8.3  Alternatives  
An alternative method of deriving human ES cells is somatic nuclear transfer, or 
cloning, which bypasses the need to destroy an embryo produced ‘naturally’ by the fusion of 
sperm and egg, which could otherwise develop to term if implanted. This was first described 
in sheep, and cloned embryos have since been generated in a number of species, (Wilmut  et 
al. 2002). 
 
Cloning human embryos could be significant for clinical development of regenerative 
medicine, especially for the reduction of the risk of rejection [of foreign cells]. However, 
cloning a human embryo, specifically for the purposes of research carries much more ethical 
issues than the use of ‘byproduct’ embryos from in vitro fertilization treatment. The even 
remote possibility of generating a live human clone has been sufficient to ban the technique 
of somatic nuclear transfer from being applied to human cells in most western countries 
(Andorno, 2002). In 2005 the U.N. General Assembly backed a resolution used by the 
committee banning all human cloning (therapeutic cloning included) to obtain stem cells 
(Cahill, 2005). 
 
Cloning of ESCs was even worse then destroying an embryo, ethically speaking, so 
the discovery of iPSCs by Yamanaka provided an answer to the ethical dilemma. It had the 
same pluripotent ability as ESCs without the need to destroy a human embryo. iPSCs are 
already valuable means when it comes to modeling of diseases and drug development and 
even though additional research is needed, scientists are optimistic regarding the use of 
iPSCs in transplantation medicine. The use of iPSCs is a great discovery and it is now 
possible to make the tissues derived from iPSCs a virtually identical match to the cell donor, 
and will as a result will be less likely to be rejected by the immune system. The strategy 
behind the use of iPSCs create pluripotent stem cells that along with studies of different types 
of pluripotent stem cells, can help scientists reprogram certain cells with the goal of repairing 
damaged tissues in the human body. (Bethesda, 2013). 
 
Much of the debate has been focus on the source of the SC’s, giving little attention to the 
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possible medical issues a future therapy may carry, table 2 shows the possible consequences 
of the use of stem cells in medicine. 
9.  Conclusion 
Stem cell research is a highly controversial subject, mostly due to the fact that human 
cells are used to create highly diversifiable stem cells. Ethically speaking the discussion, 
tends to center around a Kantian, deontological point of view where many opinions are based 
on personal beliefs, basically in the idea that experimenting with human life [embryos 
mainly] would trivialize the value of human life, this partially enforced by George W. Bush. 
 
Surprisingly Bush gave a boost to the research of stem cells, by making scientist 
explore new, and less controversial, sources to harvest SC. IPSC’s are a great example of 
those efforts, due to the fact that the ethical debate on the source of the cells can be bypassed. 
The research can now focus on how to efficiently use this new technology. 
 
At this point it is important to note that the aim of this work is not to dismiss the 
value of ethical discussion on science; on the contrary, it aims to show that it forces us to 
reevaluate the grounds of our beliefs, both in a personal and a societal level. In a personal 
level it challenges the idea of holiness of the human species by giving it the value of source 
and final recipient of the beneficial outcome.  In the societal level we are faced by the idea 
that although an embryo, that can translate into a human life, has to be destroyed for the 
prospect of relieving suffering from  people affected by incurable diseases that could be 
potentially treated in the future. It drives the idea of human preservation to a new stage, 
where the concept of right and wrong is not definable any more in the normal Kantian way. 
 
A clear example of the difficulty defining the ethical frame for stem cell research is 
seen in the ambiguous statement from the HERP in 1994, were no agreement could be reach 
between the moral status of an embryo and its scientific value. This due the fact that society 
cannot dictate right or wrong as an absolute truth. 
 
Opponents of hESC research have maintained that all pre-implantation embryos have 
the potential to become full-fledged human beings and that it is always morally wrong to 
destroy this potential (Hyun. 2010). In response to this statement it is possible to say that 
naturally not all embryos become mature and functional human beings, many embryos do not 
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have the necessary quality and therefore are not capable of producing a pregnancy. Genetic 
abnormalities alone are responsible for 75%–80% of embryos fail to implant and are lost. 
 
With the development of iPSC’s it was believed that the discussion of embryonic 
stem cells would come to an end. However, most stem cell scientists do not believe that 
iPSCs (or indeed any other “alternative source” of stem cells) can obviate the need for 
ongoing hESC research (Hyun, et al. 2007). This is mainly due to the fact that ESCs is used 
as a control to evaluate the real scientific potential of iPSCs. 
 
Also it is important to add that safety is a major issue for iPSC research intended for 
clinical applications, since the processes used for generating iPSCs could cause harmful 
mutations later in the resulting cells. 
 
With all its potential, iPSC’s are more suitable for research and understand how stem 
cells work and how specific diseases develop and can be treated, but the intrinsic risk make 
them less suitable for therapy than ESC’s. 
 
Although iPSC’s are a suitable answer to the ethical issues that concern SC’s these 
cell lines bring their own ethical challenges as well, due to the fact that somatic tissue is used 
to develop them. The idea of an iPSC line derived from a living donor entails ethical issues 
like, the re-contacting and tracking of donors, what to do with incidental findings that may 
impact a living donor’s health, and the extent and scope of donors’ reach-through rights to 
the downstream research uses and commercial benefits of their genetically matched iPSC 
lines (Hyun. 2010). 
 
Much of the debate has been focus on the source of the SC’s, giving little attention to 
the possible medical issues a future therapy may carry, table 2 shows the possible 
consequences of the use of stem cells in medicine. 
 
The truth about stem cell therapy is that even though there is great hope and 
promising results in experimental trials, there is still great challenges that have to be 
overcome to make stem cell therapy a reality (Zhongling, et al. 2009 & Segers & Lee. 2008). 
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It is important to note that many of the countries where stem cell research is limited 
by law, abortion and in vitro fertilization is allowed, this represents a moral dilemma because 
it shows a lack of ethical accordance when debating the value of life. 
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11.  Appendix 
11.1  History- Nobel Prize  
 DanStem (The Danish Center for Stem Cell Research) opened in 2011 and consists of 
two sections, BasicStem which works on basic stem cell biology and TransStem which is 
Strategic Translational Stem Cell Research and Therapy. The 9 research groups at DanStem 
focus on the basic questions regarding developmental biology and stem cell research such as 
the special properties of cancer stem cells and how progenitor cells, which are normally 
present in embryos, can develop into different kinds of cells and aim to treat diabetes and 
cancer by developing new stem cell-based therapeutic approaches.  
 
 Over the past years, the Japanese scientist Shinya Yamanka has lent his work on Stem 
cell Research to DanStem which has led to a huge improvement in the development of stem 
cell research. (DanStem, 2011) 
 
 The 2012 Nobel Prize in medicine or Physiology was given to Shinya Yamanaka 
from Japan and John B. Gurdon from England. They discovered the possibility of 
reprogramming a mature cell to become a pluripotent cell. This discovery has had a 
significant impact on stem cell research as well as have increased our understanding of how 
organisms and cells develop.  
 
 In 1962, Gurdon determined that it was possible to reprogram a mature specialized 
cell to become an immature cell which would be able to develop into all tissues of the body. 
This discovery and the techniques used has eventually led to the cloning of mammals. The 
discovery that mature stem cells under definite conditions can go back to a stem cell state has 
been made more than 40 years apart.  
 
 Regarding the development of new stem cell-based cell therapies with the goal of 
curing  chronic and severe diseases, the technologies and methods initially developed by 
Yamanaka and Gurdon are very useful. The conducted research at DanStem is based on these 
discoveries and their work on stem cell-based cell therapies targeting type 1 and 2 Diabetes 
involves both ESC's and iPSC's. (DanStem, 2012) 
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11.2  iPSC Generation 
 In 2006 Shinya Yamanaka discovered how to reprogram mouse fibroblasts to 
pluripotent stem cells by expressing certain transcription factors. To produce iPSC’s certain 
variables must be identified, such as the transcription factors used, the methods used to 
deliver these factors, the choice of target cell type, the parameters of factor expression, and 
the culture conditions used to derive iPSCs. 
 
 The first variable was finding which transcription factors mediated the somatic cells 
into pluripotent stem cells. Yamanaka found that it was Oct4 (octamer-binding transcription 
factor 4), Sox2 (sex determining region Y-box 2), c-Myc (myelocytomatosis viral oncogene 
homolog), and Klf4 ( Kruppel-like factor 4) that reprogrammed the cells. Of course different 
factors could be used as substitutes for others; however, this showed a decrease in efficiency 
(Maherali, Hochedlinger, 2008). 
 
 The method of delivery has been a more difficult obstacle to overcome due to the 
regulations needed for applicable use. Retroviruses and lentiviruses have been used for 
experimental purposes; however, as listed above, it has medical risks associated with it. 
Methods that don’t integrate in the genome have been sought after. Methods such as, 
adenoviral delivery and transient transfection don’t permanently integrate in the genome, but 
again have their own drawbacks.  
 
Table 3: Methods of Delivery  
Method Advantages Disadvantages 
Moloney based 
retrovirus     
-Silencing in pluripotent 
cells 
-self-silencing/ no need for 
timed factor withdrawal 
-risk of insertional mutagenesis 
-limited to dividing cells 
- expression often maintained/ increased 
tumor generation  
HIV-based 
lentivirus     
Constitutive    
Transduction of both 
dividing and nondividing 
cells 
Inducible 
________________ 
risk of insertional mutagenesis 
lack of silencing in pluripotent state 
________________ 
risk of insertional mutagenesis 
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temporal control over 
factor expression 
 
 
possibility of leaky expression 
Transient 
transfection 
-no viral components 
-low genomic integration 
-technically simple 
procedure 
-multiple rounds of transfection are required 
-lower levels of expression than when 
integrated 
-delayed kinetics of reprogramming 
-integration provides selective advantage and 
necessitates clone screening  
Adenovirus low genomic integration -repeated infection for certain cells types 
-delayed kinetics of programming 
-risk of generating tetraploid cells 
Table 3, (Maherali, Hochedlinger, 2008) 
 Another variable is the choice of which cells to reprogram into iPSC’s. Three 
guidelines are observed to find an appropriate cell for reprogramming. First, is the ease of 
inducing the cell into pluripotency, which varies from cell to cell. Second, is the availability 
of the cell, and finally is the age of the cell. Older cells tend to have higher risk of DNA 
damage, or lesions which cause them to be not as effective, and in some cases detrimental to 
the one receiving the cell (Maherali, Hochedlinger, 2008). 
 
 A more complicated variable and one of the least understood are the parameters of 
factor expression. After the transcription factors have been decided there is still the question 
of how long the factors should be expressed because over-expression of this factors could 
have unwanted effects (Mikkelsen et al., 2008). It has proven to be difficult to get exact 
results due to the variations in data, and also because of the differences the cells, delivery, 
and transcription factors have between each other. Getting results has been difficult because 
scientists must look at the kinetics of the programming, stoichiometry, and also the cell’s 
intrinsic characteristics. Therefore, achieving optimal expression levels has yet been 
successful (Maherali, Hochedlinger, 2008). 
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 Necessary conditions for cultures used to maintain and derive stem cells must also be 
evaluated. At the moment, animal products are used as feeder cells for stem cell derivation in 
cultures; however, the goal is to not use xeno-materials in cultures because it would be more 
clinically applicable. For instance, human ESC are very sensitive, and the use of fetal bovine 
serum (FBS) does not work well to differentiate due to the serum being biological and thus 
varies from batch to batch. Instead it is wiser to use knockout serum, which is a synthetic 
medium (Maherali, Hochedlinger, 2008). The type of serum used is not the only thing to be 
cautious of, one must also be careful when the serum is used. In some types of cells a switch 
from serum-free culture to serum-containing culture is necessary, and if switch to early will 
not produce any iPSCs. 
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12.  Glossary 
Multipotent - can develop into several cell types of the body - not just one cell type 
 
Pluripotent: The ability to give rise to all cell types of the body but can’t make extra-
embryonic tissues (components of placenta) 
 
Totipotent: can give rise to all cell types of the body additionally to all cell types that make 
up the extra-embryonic tissues such as the placenta. 
 
Apoptosis: programmed cell death. Cancer and stem cells have been shown to resist this 
mechanism, thus having an incredible proliferation rate.  
Autologous: cells that come from the same individual 
Allogeneic: Cells that come from a donor 
Syngeneic: Cells that come from an identical donor 
Immunogenicity: ability of a substance to get a response from the immune system  
 
HLA = Human Leukocyte Antigen 
MSC = Mesenchymal Stem Cells 
ASC = Adult Stem Cells 
ESC = Embryonic Stem Cells 
iPSC = induced Pluripotent Stem Cells 
FBS = Fetal Bovine Serum 
IVF = In vitro Fertilization 
AD = Alzheimer’s Disease 
MiPSC = Mouse induced Pluripotent Stem Cell 
hESC = human Embryonic Stem Cell 
MHC = Major Histocompatibility Complex 
SCT = 
NSC = Neural Stem Cell 
GVHD = Graft Versus Host Disease 
 
 
 
